Quest Diagnostics Incorporated logo
DGXQuest Diagnostics Incorporated

Debt to Equity Ratio: 0.95

popular:market cap|pe ratio|revenue|price history|total return

Is the debt to equity ratio high or low?

The debt to equity ratio of 0.95 is 15% above its 5-year average of 0.83, near the high end of its 5-year range (0.69–1.02).

As of Friday, June 26, 2026. 2.48% above its 12-month average of 0.92.

Current Ratio|Quick Ratio|ROE|All Metrics
Debt to Equity

DGX Debt to Equity Ratio

0.95

Reported quarterly debt to equity ratio; no daily interpolation.

+20.29% 5Y
DGX Debt to Equity Ratio

DGX Average Debt to Equity Ratio Chart

DGX Debt to Equity Ratio

DGX Current vs Average Debt to Equity Ratio Chart

DGX Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.95

DEBT TO EQUITY RATIO AVG TTM

0.92

DEBT TO EQUITY RATIO AVG 3Y

0.88

DEBT TO EQUITY RATIO AVG 5Y

0.83

DEBT TO EQUITY RATIO AVG 10Y

0.80

DEBT TO EQUITY RATIO AVG 15Y

0.84

DEBT TO EQUITY RATIO AVG 20Y

0.84

CURRENT VS TTM AVG

+2.48%

CURRENT VS 3Y AVG

+7.65%

CURRENT VS 5Y AVG

+14.66%

CURRENT VS 10Y AVG

+17.79%

CURRENT VS 15Y AVG

+12.44%

CURRENT VS 20Y AVG

+13.16%

DGX Competitors' Debt to Equity Ratio

NAMEMARKET CAPDEBT TO EQUITY RATIOTTM3Y5Y
Quest Diagnostics Incorporated (DGX)$22.83B0.950.920.880.83
BioNTech SE (BNTX)vs ›$22.76B0.010.010.010.04
United Therapeutics Corporation (UTHR)vs ›$23.07B0.000.030.090.13
Moderna, Inc. (MRNA)vs ›$23.71B0.220.150.110.10
Labcorp Holdings Inc. (LH)vs ›$21.83B0.840.870.780.74
Incyte Corporation (INCY)vs ›$21.48B0.010.010.010.01
Waters Corporation (WAT)vs ›$24.57B0.580.761.732.93
Mettler-Toledo International Inc. (MTD)vs ›$25.13B-99.1448.2326.0617.96
STERIS plc (STE)vs ›$20.52B0.290.310.420.44
Veeva Systems Inc. (VEEV)vs ›$25.68B0.010.010.010.02

Financial Health

Debt/Equity

0.95

Current Ratio

1.04

Debt to Equity Ratio Formula & Definition

Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Quest Diagnostics Incorporated (DGX)?
The debt to equity ratio for DGX stock is 0.95.
Is Quest Diagnostics Incorporated's debt to equity ratio high or low?
The debt to equity ratio of 0.95 is 15% above its 5-year average of 0.83, near the high end of its 5-year range (0.69–1.02).
What is the TTM average debt to equity ratio for Quest Diagnostics Incorporated (DGX)?
The TTM average debt to equity ratio for DGX stock is 0.92.
What is the 3Y average debt to equity ratio for Quest Diagnostics Incorporated (DGX)?
The 3Y average debt to equity ratio for DGX stock is 0.88.
What is the 5Y average debt to equity ratio for Quest Diagnostics Incorporated (DGX)?
The 5Y average debt to equity ratio for DGX stock is 0.83.
What is the 10Y average debt to equity ratio for Quest Diagnostics Incorporated (DGX)?
The 10Y average debt to equity ratio for DGX stock is 0.80.
What is the 15Y average debt to equity ratio for Quest Diagnostics Incorporated (DGX)?
The 15Y average debt to equity ratio for DGX stock is 0.84.
What is the 20Y average debt to equity ratio for Quest Diagnostics Incorporated (DGX)?
The 20Y average debt to equity ratio for DGX stock is 0.84.

DGX Debt to Equity Ratio History

DATEDEBT TO EQUITY RATIO
2026-03-310.95
2025-12-310.96
2025-09-300.88
2025-06-300.88
2025-03-310.95
2024-12-311.02
2024-09-301.02
2024-06-300.77
2024-03-310.83
2023-12-310.85
2023-09-300.76
2023-06-300.79
2023-03-310.76
2022-12-310.78
2022-09-300.74
2022-06-300.72
2022-03-310.73
2021-12-310.72
2021-09-300.73
2021-06-300.79
2021-03-310.69
2020-12-310.69
2020-09-300.80
2020-06-300.88
2020-03-310.81
2019-12-310.94
2019-09-300.81
2019-06-300.83
2019-03-310.90
2018-12-310.75
2018-09-300.70
2018-06-300.71
2018-03-310.77
2017-12-310.77
2017-09-300.79
2017-06-300.80
2017-03-310.81
2016-12-310.81
2016-09-300.82
2016-06-300.85
2016-03-310.84
2015-12-310.78
2015-09-300.81
2015-06-300.87
2015-03-311.12
2014-12-310.87
2014-09-300.92
2014-06-300.97
2014-03-310.99
2013-12-310.84
2013-09-300.88
2013-06-300.89
2013-03-310.81
2012-12-310.81
2012-09-300.85
2012-06-300.96
2012-03-311.01
2011-12-311.09
2011-09-301.19
2011-06-301.26
2011-03-311.24
2010-12-310.74
2010-09-300.82
2010-06-300.80
2010-03-310.80
2009-12-310.78
2009-09-300.76
2009-06-300.82
2009-03-310.87
2008-12-310.86
2008-09-300.84
2008-06-300.89
2008-03-310.98
2007-12-311.07
2007-09-301.13
2007-06-301.23
2007-03-310.66
2006-12-310.52
2006-09-300.51
2006-06-300.53
2006-03-310.53
2005-12-310.58
2005-09-300.30
2005-06-300.31
2005-03-310.32
2004-12-310.48
2004-09-300.44
2004-06-300.45
2004-03-310.44
2003-12-310.46
2003-09-300.47
2003-06-300.48
2003-03-310.55
2002-12-310.47
2002-09-300.62
2002-06-300.72

Related Metrics

Current RatioQuick RatioROEAll Metrics

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

Secaucus, NJ
55,000 employees
www.questdiagnostics.com
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James E. Davis
View full financials